Optimal response to dimethyl fumarate is mediated by a reduction of Th1‐like Th17 cells after 3 months of treatment

AIM: Dimethyl fumarate (DMF) is one of the most promising therapies for relapsing‐remitting multiple sclerosis (RRMS) patients since it has shown immunomodulatory and neuroprotective effects. However, a percentage of RRMS patients do not exhibit an optimal response to DMF. The objective of this stud...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:CNS Neurosci Ther
Main Authors: Mansilla, María José, Navarro‐Barriuso, Juan, Presas‐Rodríguez, Silvia, Teniente‐Serra, Aina, Quirant‐Sánchez, Bibiana, Ramo‐Tello, Cristina, Martínez‐Cáceres, Eva María
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6698982/
https://ncbi.nlm.nih.gov/pubmed/31066225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.13142
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki